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Edited by Horst FeldmannAbstract The sequence requirement for N-terminal cleavage
and the proteasomal degradation of p27Kip1 and their relationship
was investigated. Residues 5–8 were required for the cleavage
and the mutation of S10 to E inhibited the cleavage. The C-
terminal PEST sequence was necessary for the degradation and
residue R165 was found to play an important role in the
degradation. The inhibition of the cleavage by deleting residues
5–8 inhibited the degradation, while the fragment mimicking the
cleavage product accelerated the degradation. Both the cleavage
and degradation demonstrated a similar sensitivity toward
proteasome inhibitors and ATP depletion. These two processes
are thus suggested to be tightly linked and sequential.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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p27Kip1 is a cyclin-dependent kinase (Cdk) inhibitor which
causes growth arrest in response to anti-mitogenic signals such
as serum starvation and cell–cell contact [1,2]. The mitogenic
stimulation causes a rapid downregulation of p27Kip1 before
the quiescent cells return to the cell cycle and progress into the
S phase [3,4]. Among the transcriptional and post-transcrip-
tional mechanisms regulating the level of p27Kip1, the proteo-
lytic degradation plays an important role in the rapid
downregulation and inactivation of p27Kip1 [5,6]. The ubiqui-
tination-proteasome pathway plays an important role in the
degradation of p27Kip1, while the calpain-mediated ubiquitin-
independent degradation mechanism has also been reported to
degrade p27Kip1 [5,7]. Skp2 was shown to mediate the ubiq-
uitination of p27Kip1 [7,8]. However, p27Kip1 was found to be
degraded in Skp2= mice during G1/S transition [9]. On the
other hand, the phosphorylation of p27Kip1 has been reported
to regulate degradation [10–13]. The phosphorylation of T187* Corresponding author. Fax: +81-92-642-5552.
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tion [11]. However, the knock-in mice of p27Kip1 with a mu-
tation of T187 to A revealed a degradation mechanism
independent of T187 phosphorylation, which works during the
G1/S transition [14]. On the other hand, the phosphorylation
of S10 was shown to stabilize p27Kip1 against degradation
during the G1/S transition [12,13]. In addition to the protea-
some-mediated degradation, the N-terminal cleavage has also
been reported to contribute to the functional downregulation
of p27Kip1 [6]. However, the sequence requirement for the
proteasomal degradation and the N-terminal cleavage of
p27Kip1, and the relationship between these two proteolytic
mechanisms remain to be elucidated.
We have previously cloned a second isoform of p27Kip1
(p27Kip1R), which was found to be resistant to both N-terminal
cleavage and proteasomal degradation [15]. In a preliminary
experiment, a fragment consisting of the region 1–162 common
to both isoforms (Fig. 1(a)) was found to undergo only N-
terminal cleavage, but it was resistant to proteasomal degra-
dation. In the present study, taking our initial observation into
account, we separately clariﬁed some of the sequences required
for the N-terminal cleavage and the proteasomal degradation.
Furthermore, the initial observation allowed us, for the ﬁrst
time, to uncover the relationship between N-terminal cleavage
and the proteasomal degradation. Our observations suggest
that the two proteolytic processes are tightly linked and they
may also be sequential.2. Materials and methods
2.1. Construction of plasmids
All recombinant proteins of p27Kip1, p27Kip1R and their mutants
were expressed in bacteria as hexahistidine-tagged proteins using
pQE32 (Qiagen, Hilden, Germany) as an expression vector. The full-
length p27Kip1 consisting of 198 residues (refer to as Kip11–198) was the
same as previously described [1,15]. Because the original clone of
p27Kip1R (pAD-K4) lacked the N-terminal 8 amino acids [15], the full
length p27Kip1R (Kip1R1–180) was constructed by connecting a 50 part
of p27Kip1 and a 30 part of pAD-K4 using an overlap extension PCR
[16]. The truncation mutants were obtained by PCR ampliﬁcation
using speciﬁc primer sets. The site-directed mutants were obtained with
an overlap extension PCR using complementary primers containing
the intended mutations, as previously described [15,17]. The mutants
used in the present study are Kip11–162 (a fragment containing residuesblished by Elsevier B.V. All rights reserved.
Fig. 1. Time course of the degradation of p27Kip1, p27Kip1R and the C-
terminally truncated p27Kip1. (a) The schematic presentation of the
structure of two isoforms of p27Kip1. The region 1–162 is common to
the two isoforms [15]. Closed boxes, the cyclin-binding and Cdk-
binding regions [12,24]; the hatched boxes, potential (residues 169–190)
and poor (residues 5–15) PEST sequences as determined by a PEST-
FIND program [21]; cross-hatched box, a C-terminal region speciﬁc to
p27Kip1R. The amino acid sequences of the putative PEST sequences
are shown. (b–e) Representative immunoblots showing the time course
of degradation of Kip11–198 and Kip1R1–180 (b, c) and the C-terminally
truncated p27Kip1 (d, e) catalyzed by the extracts of endothelial cells in
the late G1 phase (b, d) and HeLa cells in the S phase (c, e). The photos
are representatives of three independent experiments. The triangles
indicate a cleavage product. In (d) and (e), two representative degra-
dation patterns of Kip11–162 are shown to indicate that the activity of
cleavage varied somewhat from preparation to preparation of the cell
extracts.
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Kip118–162, Kip19–198, Kip118–198, Kip11–162=R5A (Kip11–162 containing a
mutation of R5 to A), Kip11–162=S10A, Kip11–162=S10E, Kip118–198=K165R,
Kip118–198=K153R=K165R and Kip118–198=K134R=K153R=K165R (Fig. 1(a)). The
nucleotide sequences of all constructs were determined to contain no
unintended mutation.
2.2. Expression and puriﬁcation of recombinant protein
The recombinant proteins were expressed in Escherichia coli JM109
for 4 h as previously described [1,15]. The cells were homogenized in
buﬀer A (6 M guanidine HCl, 0.1 M sodium phosphate and 10 mM
Tris–HCl, pH 8.0) and then subjected to aﬃnity puriﬁcation using aNi2þ-loaded HiTrap aﬃnity column on an €AKTA prime liquid chro-
matography device (Amersham Pharmacia Biotech, Tokyo, Japan).
The column was washed in buﬀer A and in buﬀer B (6 M urea, 0.1 M
sodium phosphate and 10 mM Tris–HCl, pH 6.3) and then eluted in
buﬀer B containing 0.5 M imidazole-HCl. The pooled peak fractions
were dialyzed against 30 mM Tris–HCl and 30 mM NaCl, pH 7.5.
Because of the low solubility after dialysis, Kip1R1–180 was re-natured
on the column as previously described [18], and the column eluates
were then directly used in an assay.
2.3. Cell culture and cell cycle synchronization
The endothelial cells of the porcine thoracic aortas (5–16 passages)
and HeLa cells were cultured as previously described [1,15]. Endo-
thelial cells were synchronized at the late G1 phase of the cell cycle by
harvesting cells at 15 h after seeding the growth arrested conﬂuent
endothelial cells at a 50% conﬂuent density [1,15]. HeLa cells were
synchronized at the S phase by harvesting the cells 3 h after the release
from the 24-h block by 2 mM hydroxyurea [1,15,19].
2.4. In vitro degradation assay
The hypotonic cell extract was prepared in 20 mM HEPES, 5.0 mM
KCl, 1.5 mM MgCl2, and 1.0 mM dithiothreitol, pH 7.5 as previously
described [15]. The in vitro degradation assay was started by mixing 10
ll of cell extract supplemented with 25 mM phosphocreatine and 10
lg/ml creatine kinase, 30 ng of recombinant protein and 1 mM ATP
unless otherwise speciﬁed at 30 C for each time point. The samples
were withdrawn at 0, 0.5, 1, 2 and 3 h, and were then subjected to an
immunoblot analysis using anti-p27Kip1 antibody (BD Biosciences,
Tokyo, Japan) and enhanced chemiluminescence technique, as previ-
ously described [1,15]. The densities of the bands were determined with
the NIH image ver1.61 (National Institute of Health, Bethesda, MD,
USA) after obtaining the chemiluminescence images on X-ray ﬁlm
with a CCD camera.
2.5. Statistical analysis
Student’s t test was used to determine statistical signiﬁcance between
the two groups. P values of less than 0.05 were considered to be
signiﬁcant.3. Results
3.1. Diﬀerences in the degradation pattern between p27Kip1 and
p27Kip1R
Fig. 1 demonstrates representative patterns of degradation
of Kip11–198 and Kip1R1–180 catalyzed by the extract of
endothelial cells (Fig. 1(b)) and HeLa cells (Fig. 1(c)). In
both cell types, Kip11–198 degraded within 3 h. It is note-
worthy that an intermediate product was observed in both
cell types during the degradation of Kip11–198. The product
(28.1 kDa) was approximately 2.5 kDa smaller than
Kip11–198 (30.7 kDa), as estimated on SDS–PAGE. On the
other hand, Kip1R1–180 was resistant to degradation, and no
such intermediate product as that seen with Kip11–198 was
observed.
3.2. The region 1–162 is sensitive to cleavage but resistant to
degradation
The diﬀerence in the susceptibility to degradation between
two isoforms was considered to be due to the diﬀerence in the
C-terminus. We thus ﬁrst examined the degradation of
Kip11–162, the region common to two isoforms to determine
the structural basis for the diﬀerence in the degradation pat-
tern (Fig. 1(a)). In both endothelial cells (Fig. 1(d)) and HeLa
cells (Fig. 1(e)), Kip11–162 was cleaved to a fragment which was
approximately 2.5 kDa smaller than Kip11–198 with no further
degradation, although the activity of cleavage varied some-
what from preparation to preparation of the cell extracts. The
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(Kip11–166) did not restore the susceptibility to degradation,
while the addition of 163–190 (Kip11–190) restored the sus-
ceptibility toward degradation similar to that observed with
Kip11–198 (Fig. 1(d) and (e)). The intermediate product was
also observed during the degradation of Kip11–190. It is note-
worthy that the reduction of molecular size by the cleavage
was 2.5 kDa and similar in all mutants despite the diﬀer-
ence in the C-terminal length. This observation thus suggests
that the cleavage removed a 2.5 kDa fragment from the
N-terminus.
3.3. Sequences requirement for the N-terminal cleavage
The cleavage of the mutants of Kip11–162 was examined to
determine the sequences required for the N-terminal cleavage
without interference by the proteasomal degradation (Fig. 2).
The deletion of 4 amino acids from the N-terminus (Kip15–162)
did not inhibit the N-terminal cleavage, while the deletion of 8
residues (Kip19–162) completely inhibited the N-terminal
cleavage in both cells types (Fig. 2). The residues 5–8 were thus
necessary for the cleavage. The further deletion of 10 residues
(Kip118–162) was also resistant to cleavage. However, Kip118–162
demonstrated a similar mobility on the SDS–PAGE to that of
the cleavage product derived from Kip11–162 when applied
side-by-side (data not shown). Kip118–162 was thus considered
to represent a cleavage product. The mutation of R5 to A of
Kip11–162 (Kip11–162=R5A) completely inhibited the N-terminal
cleavage. The mutation of S10 to E (Kip11–162=S10E) inhibitedFig. 2. Sequence requirement for the N-terminal cleavage of Kip11–162.
Representative immunoblots showing the time course of degradation
for the mutants of Kip11–162 catalyzed by the extract of endothelial
cells in the late G1 phase (a) and HeLa cells in the S phase (b).the N-terminal cleavage, while the mutation to A
(Kip11–162=S10A) had no apparent eﬀect.
3.4. Eﬀect of N-terminal cleavage on the proteasomal
degradation of p27Kip1 and the requirement of K165 for
degradation
In order to elucidate the relationship between the N-terminal
cleavage and proteasomal degradation, we compared the
degradation of Kip11–198, Kip19–198 and Kip118–198 (Fig. 3).
According to the observations shown in Fig. 2, Kip19–198 was
considered to be resistant to the N-terminal cleavage, while
Kip118–198 was considered to mimic the N-terminally cleaved
p27Kip1. The degradation of Kip19–198 was signiﬁcantly slower
than that observed with Kip11–198. The degradation of
Kip118–198 was signiﬁcantly enhanced compared to that ob-
served with Kip11–198.
K134, K153 and K165 have been previously reported to
play an important role in the ubiquitination and sub-
sequent degradation of p27Kip1 [6]. The mutation of K165
to A markedly inhibited the degradation of Kip118–198.
However, the degradations of Kip118–198=K153R=K165R and
Kip118–198=K134R=K153R=K165R were similar to that observed
for Kip118–198=K165R (data not shown).
3.5. Eﬀect of protease inhibitors and ATP depletion on the
N-terminal cleavage and proteasomal degradation
To separately determine the sensitivity of the N-terminal
cleavage andproteasomal degradation to the protease inhibitorsFig. 3. Eﬀects of the N-terminal cleavage on the degradation of
p27Kip1. Representative immunoblots (a) and summary (b) of the time
course of degradation of Kip11–198, Kip19–198, Kip118–198 and
Kip118–198=K165R catalyzed by the extract of endothelial cells in the late
G1 phase. The data are means S.E. (n ¼ 5). *P < 0:05 vs. Kip11–198.
Fig. 4. Eﬀects of proteasome inhibitor and ATP depletion on the N-
terminal cleavage and the degradation of p27Kip1. Representative im-
munoblots showing the N-terminal cleavage of Kip11–162 (a) and the
degradation of Kip118–198 (b) catalyzed by the extract of endothelial
cells in the late G1 phase. The recombinant proteins were incubated
with the cell extract for 3 h under the indicated conditions. Input, the
sample obtained at time 0; control, the sample obtained after 3 h in-
cubation with the cell extract in the absence of inhibitors and the
presence of 1 mM ATP; 0 ATP, the samples obtained with no sup-
plementation of ATP. ATPcS was added at the indicated concentra-
tions in place of ATP.
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and ATP depletion, the cleavage of Kip11–162 and the degrada-
tion of Kip118–198 were examined (Fig. 4). Interestingly, both
N-terminal cleavage and proteasomal degradation showed a
similar sensitivity toward the same set of protease inhibitors
(MG132, MG115, calpain inhibitor I, and leupeptin) and the
addition of ATPcS, a non-hydrolyzable ATP analog.4. Discussion
The key ﬁnding in the present study is that the region 1–162
common to p27Kip1 and p27Kip1R was resistant to degradation
but susceptible to limited proteolysis. The limited proteolysis
was suggested to remove an approximately 2.5 kDa fragment
from the N-terminus. This fact enabled us to separately de-
termine the structural basis for the N-terminal cleavage and
the proteasomal degradation and to examine their relation-
ship. The most important and novel ﬁnding of the present
study is that the inhibition of the N-terminal cleavage inhibited
proteasomal degradation, while the fragment mimicking the
product of N-terminal cleavage degraded faster than the wild
type. Our ﬁndings thus suggest that the N-terminal cleavage
helps p27Kip1 to undergo further degradation by proteasome.
However, the fragment resistant to N-terminal cleavage still
degraded. The N-terminal cleavage may thus not be an abso-
lute requirement for proteasomal degradation. Since both N-terminal cleavage and proteasomal degradation exhibited the
same sensitivity to proteasome inhibitors and ATP depletion,
these two processes are thus suggested to be tightly linked and
a sequential process probably catalyzed by the same machin-
ery, namely proteasome.
The similar N-terminal cleavage of p27Kip1 has been previ-
ously reported [6]. This report suggested that the cleavage
removed an approximately 5 kDa fragment containing a cy-
clin-binding domain from the N-terminus, thus inactivating
p27Kip1 as a Cdk inhibitor. On the other hand, the N-terminal
cleavage seen in the present study is suggested to remove ap-
proximately 20 residues but not the cyclin-binding domain,
thus leaving p27Kip1 active as a Cdk inhibitor [20]. Therefore, a
further degradation is needed to inactivate p27Kip1. Although
the N-terminal cleavage per se does not inactivate p27Kip1, it
facilitates the inactivation of p27Kip1 by accelerating prote-
asomal degradation.
The extension of residues 163–190 to Kip11–162 was found to
restore susceptibility toward degradation. This extension
contains a region 169–189 that is found to be a possible PEST
sequence with a PEST-FIND score of +11.06 (Fig. 1(a))
[21,22]. A previous report suggested the possibility that this
PEST sequence is involved in the calpain-mediated cleavage of
p27Kip1 [23]. Our ﬁndings suggest that the PEST sequence at
the C-terminal region of p27Kip1 plays an important role in the
proteasomal degradation but not in the N-terminal cleavage of
p27Kip1. On the other hand, the proteasomal degradation of
p27Kip1 is dependent on ubiquitination [5–7]. K134, K153 and
K165 were previously reported to serve as major ubiquitina-
tion sites [6]. Our ﬁndings suggest that K165 plays the most
critical role among them. The critical role of K165 is consistent
with the fact that K134 and K153 reside in the region common
to p27Kip1 and p27Kip1R, while K165 resides in the C-terminal
region speciﬁc to p27Kip1 and at the proximity of the PEST
sequence (Fig. 1(a)).
The present study clariﬁed that residues 5–8 are necessary
for the N-terminal cleavage and that the mutation mimicking
the phosphorylation at S10 stabilizes p27Kip1 against the
proteolytic cleavage. The residues 5–8 are located in the re-
gion 5–15 that is found to be a poor PEST sequence (PEST-
FIND score of )9.92) [21,22]. The PEST sequence is deﬁned
as hydrophilic stretches containing at least one P, one E or
D and one S or T, and ﬂanked by K, R or H residues [21].
The inhibition of the N-terminal cleavage in Kip11–162=R5A
may support the involvement of the PEST sequence. How-
ever, the signiﬁcance of this region as a PEST sequence re-
mains to be determined. The mutation mimicking the
phosphorylation at S10 has been previously reported to
stabilize p27Kip1 [12,13]. Our observations suggest that this
stabilization of p27Kip1 is primarily due to the inhibition of
N-terminal cleavage, which in turn stabilizes p27Kip1 against
proteasomal degradation.
p27Kip1R was resistant to both N-terminal cleavage and
proteasomal degradation. This resistance to proteasomal
degradation is probably due to the lack of a PEST se-
quence seen in the C-terminal region speciﬁc to p27Kip1. The
C-terminal region speciﬁc to p27Kip1R is thus suggested to
inhibit the N-terminal cleavage. However, its mechanism
remains to be elucidated.
In conclusion, N-terminal cleavage and proteasomal degra-
dation of p27Kip1 are suggested to be tightly linked and are also
considered to occur as a sequential process mediated by the
K. Hirano et al. / FEBS Letters 574 (2004) 111–115 115same proteolytic mechanism. This cleavage facilitates further
degradation of p27Kip1 by proteasome.
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